Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP

In recent years, next-generation sequencing (NGS)–based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope has broadened to encompass aiding in pathological diagnosis and exploring resis...

Full description

Saved in:
Bibliographic Details
Published inJournal of pathology and translational medicine Vol. 58; no. 4; pp. 147 - 164
Main Authors Kim, Miso, Shim, Hyo Sup, Kim, Sheehyun, Lee, In Hee, Kim, Jihun, Yoon, Shinkyo, Kim, Hyung-Don, Park, Inkeun, Jeong, Jae Ho, Yoo, Changhoon, Cheon, Jaekyung, Kim, In-Ho, Lee, Jieun, Hong, Sook Hee, Park, Sehhoon, Jung, Hyun Ae, Kim, Jin Won, Kim, Han Jo, Cha, Yongjun, Lim, Sun Min, Kim, Han Sang, Lee, Choong-Kun, Kim, Jee Hung, Chun, Sang Hoon, Yun, Jina, Park, So Yeon, Lee, Hye Seung, Cho, Yong Mee, Nam, Soo Jeong, Yoon, Sun Och, Lee, Ahwon, Jang, Kee-Taek, Yun, Hongseok, Lee, Sungyoung, Kim, Jee Hyun, Kim, Wan-Seop
Format Journal Article
LanguageEnglish
Published Korea (South) Korean Society of Pathologists, Korean Society for Cytopathology 01.07.2024
The Korean Society of Pathologists and the Korean Society for Cytopathology
Korean Society of Pathologists & the Korean Society for Cytopathology
대한병리학회
Subjects
Biomarkers
Bone cancer
Clinical medicine
Clinical trials
Ewings sarcoma
FDA approval
Genes
Genetic testing
Kidney cancer
korea
Metastasis
Mutation
next-generation sequencing
Oncology
Patients
Precision medicine
Regulatory approval
Review
Rhabdomyosarcoma
solid cancer
Tumors
병리학
Next-generation sequencing
Solid cancer
Precision medicine
Korea
Online AccessGet full text
ISSN2383-7837
2383-7845
2383-7845
DOI10.4132/jptm.2023.11.01

Cover

Abstract In recent years, next-generation sequencing (NGS)–based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope has broadened to encompass aiding in pathological diagnosis and exploring resistance mechanisms. With the ongoing expansion in NGS application and reliance, a compelling necessity arises for expert consensus on its application in solid cancers. To address this demand, the forthcoming recommendations not only provide pragmatic guidance for the clinical use of NGS but also systematically classify actionable genes based on specific cancer types. Additionally, these recommendations will incorporate expert perspectives on crucial biomarkers, ensuring informed decisions regarding circulating tumor DNA panel testing.
AbstractList In recent years, next-generation sequencing (NGS)–based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope has broadened to encompass aiding in pathological diagnosis and exploring resistance mechanisms. With the ongoing expansion in NGS application and reliance, a compelling necessity arises for expert consensus on its application in solid cancers. To address this demand, the forthcoming recommendations not only provide pragmatic guidance for the clinical use of NGS but also systematically classify actionable genes based on specific cancer types. Additionally, these recommendations will incorporate expert perspectives on crucial biomarkers, ensuring informed decisions regarding circulating tumor DNA panel testing. KCI Citation Count: 0
In recent years, next-generation sequencing (NGS)–based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope has broadened to encompass aiding in pathological diagnosis and exploring resistance mechanisms. With the ongoing expansion in NGS application and reliance, a compelling necessity arises for expert consensus on its application in solid cancers. To address this demand, the forthcoming recommendations not only provide pragmatic guidance for the clinical use of NGS but also systematically classify actionable genes based on specific cancer types. Additionally, these recommendations will incorporate expert perspectives on crucial biomarkers, ensuring informed decisions regarding circulating tumor DNA panel testing.
In recent years, next-generation sequencing (NGS)-based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope has broadened to encompass aiding in pathological diagnosis and exploring resistance mechanisms. With the ongoing expansion in NGS application and reliance, a compelling necessity arises for expert consensus on its application in solid cancers. To address this demand, the forthcoming recommendations not only provide pragmatic guidance for the clinical use of NGS but also systematically classify actionable genes based on specific cancer types. Additionally, these recommendations will incorporate expert perspectives on crucial biomarkers, ensuring informed decisions regarding circulating tumor DNA panel testing.In recent years, next-generation sequencing (NGS)-based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope has broadened to encompass aiding in pathological diagnosis and exploring resistance mechanisms. With the ongoing expansion in NGS application and reliance, a compelling necessity arises for expert consensus on its application in solid cancers. To address this demand, the forthcoming recommendations not only provide pragmatic guidance for the clinical use of NGS but also systematically classify actionable genes based on specific cancer types. Additionally, these recommendations will incorporate expert perspectives on crucial biomarkers, ensuring informed decisions regarding circulating tumor DNA panel testing.
Author Park, So Yeon
Park, Sehhoon
Kim, Hyung-Don
Jeong, Jae Ho
Kim, Jee Hung
Yoon, Sun Och
Jang, Kee-Taek
Lee, Jieun
Nam, Soo Jeong
Kim, Miso
Yoo, Changhoon
Kim, Sheehyun
Cha, Yongjun
Kim, Jihun
Lee, Ahwon
Yun, Hongseok
Kim, Jee Hyun
Kim, Jin Won
Hong, Sook Hee
Lee, Sungyoung
Cheon, Jaekyung
Chun, Sang Hoon
Cho, Yong Mee
Lee, In Hee
Yun, Jina
Kim, Han Sang
Jung, Hyun Ae
Lee, Hye Seung
Park, Inkeun
Yoon, Shinkyo
Lee, Choong-Kun
Kim, In-Ho
Shim, Hyo Sup
Kim, Han Jo
Lim, Sun Min
Kim, Wan-Seop
Author_xml – sequence: 1
  givenname: Miso
  orcidid: 0000-0002-4064-4199
  surname: Kim
  fullname: Kim, Miso
– sequence: 2
  givenname: Hyo Sup
  orcidid: 0000-0002-5718-3624
  surname: Shim
  fullname: Shim, Hyo Sup
– sequence: 3
  givenname: Sheehyun
  orcidid: 0000-0002-4347-4420
  surname: Kim
  fullname: Kim, Sheehyun
– sequence: 4
  givenname: In Hee
  orcidid: 0000-0002-0139-9768
  surname: Lee
  fullname: Lee, In Hee
– sequence: 5
  givenname: Jihun
  orcidid: 0000-0002-8694-4365
  surname: Kim
  fullname: Kim, Jihun
– sequence: 6
  givenname: Shinkyo
  orcidid: 0000-0001-7544-0404
  surname: Yoon
  fullname: Yoon, Shinkyo
– sequence: 7
  givenname: Hyung-Don
  orcidid: 0000-0001-9959-0642
  surname: Kim
  fullname: Kim, Hyung-Don
– sequence: 8
  givenname: Inkeun
  orcidid: 0000-0003-3064-7895
  surname: Park
  fullname: Park, Inkeun
– sequence: 9
  givenname: Jae Ho
  orcidid: 0000-0002-8749-2612
  surname: Jeong
  fullname: Jeong, Jae Ho
– sequence: 10
  givenname: Changhoon
  orcidid: 0000-0002-1451-8455
  surname: Yoo
  fullname: Yoo, Changhoon
– sequence: 11
  givenname: Jaekyung
  orcidid: 0000-0001-8439-1739
  surname: Cheon
  fullname: Cheon, Jaekyung
– sequence: 12
  givenname: In-Ho
  orcidid: 0000-0002-0351-2074
  surname: Kim
  fullname: Kim, In-Ho
– sequence: 13
  givenname: Jieun
  orcidid: 0000-0002-2656-0650
  surname: Lee
  fullname: Lee, Jieun
– sequence: 14
  givenname: Sook Hee
  orcidid: 0000-0003-4299-5694
  surname: Hong
  fullname: Hong, Sook Hee
– sequence: 15
  givenname: Sehhoon
  orcidid: 0000-0001-9467-461X
  surname: Park
  fullname: Park, Sehhoon
– sequence: 16
  givenname: Hyun Ae
  orcidid: 0000-0002-1583-4142
  surname: Jung
  fullname: Jung, Hyun Ae
– sequence: 17
  givenname: Jin Won
  orcidid: 0000-0002-1357-7015
  surname: Kim
  fullname: Kim, Jin Won
– sequence: 18
  givenname: Han Jo
  orcidid: 0000-0002-5721-1728
  surname: Kim
  fullname: Kim, Han Jo
– sequence: 19
  givenname: Yongjun
  orcidid: 0000-0001-5651-7939
  surname: Cha
  fullname: Cha, Yongjun
– sequence: 20
  givenname: Sun Min
  orcidid: 0000-0001-7694-1593
  surname: Lim
  fullname: Lim, Sun Min
– sequence: 21
  givenname: Han Sang
  orcidid: 0000-0002-6504-9927
  surname: Kim
  fullname: Kim, Han Sang
– sequence: 22
  givenname: Choong-Kun
  orcidid: 0000-0001-5151-5096
  surname: Lee
  fullname: Lee, Choong-Kun
– sequence: 23
  givenname: Jee Hung
  orcidid: 0000-0002-9044-8540
  surname: Kim
  fullname: Kim, Jee Hung
– sequence: 24
  givenname: Sang Hoon
  orcidid: 0000-0002-5847-7317
  surname: Chun
  fullname: Chun, Sang Hoon
– sequence: 25
  givenname: Jina
  orcidid: 0000-0001-5897-8309
  surname: Yun
  fullname: Yun, Jina
– sequence: 26
  givenname: So Yeon
  orcidid: 0000-0002-0299-7268
  surname: Park
  fullname: Park, So Yeon
– sequence: 27
  givenname: Hye Seung
  orcidid: 0000-0002-1667-7986
  surname: Lee
  fullname: Lee, Hye Seung
– sequence: 28
  givenname: Yong Mee
  orcidid: 0000-0001-8766-2602
  surname: Cho
  fullname: Cho, Yong Mee
– sequence: 29
  givenname: Soo Jeong
  orcidid: 0000-0001-9376-359X
  surname: Nam
  fullname: Nam, Soo Jeong
– sequence: 31
  givenname: Sun Och
  orcidid: 0000-0002-5115-1402
  surname: Yoon
  fullname: Yoon, Sun Och
– sequence: 32
  givenname: Ahwon
  orcidid: 0000-0002-2523-9531
  surname: Lee
  fullname: Lee, Ahwon
– sequence: 33
  givenname: Kee-Taek
  orcidid: 0000-0001-7987-4437
  surname: Jang
  fullname: Jang, Kee-Taek
– sequence: 34
  givenname: Hongseok
  orcidid: 0000-0003-2776-5954
  surname: Yun
  fullname: Yun, Hongseok
– sequence: 35
  givenname: Sungyoung
  orcidid: 0000-0003-3458-1440
  surname: Lee
  fullname: Lee, Sungyoung
– sequence: 36
  givenname: Jee Hyun
  orcidid: 0000-0003-1336-3620
  surname: Kim
  fullname: Kim, Jee Hyun
– sequence: 37
  givenname: Wan-Seop
  orcidid: 0000-0001-7704-5942
  surname: Kim
  fullname: Kim, Wan-Seop
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39026440$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003101610$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNqFUk1vEzEQXaEiWkrP3JAlLggpqT_3g0tVRXxEFBVBOVter5049dqL7aX0N_Cn8SYloj3Aaazxmzdv5s3T4sB5p4riOYJzigg-3Qypn2OIyRyhOUSPiiNMajKrasoO9m9SHRYnMW4ghIgyUtLmSXFIGohLSuFR8WthjTNSWDAEIZORCgQlfd8r14lkvItA-wDSWoExKuA1cOpnmq2UU2H7D6L6PionjVsB48CQk8qlCG5MWoPoremAFE6q8AYIsPHGpdxg8CEBHXwPPn79dAmE6_Lj87PisRY2qpO7eFx8e_f2avFhdnH5frk4v5jJPECaIYJYK5mEshElwVjUmuRZUCuY6DrYVBQpprSupWBE4wqJusVQYoxk05S4JsfF6x2vC5pfS8O9MNu48vw68PMvV0uOIGOoKlEGL3fgzosNH4LpRbjdVmwTPqy4CHlvVnFKtW5r1LKaZqU5kFZrgjRlpZJYNZkL7rhGN4jbG2HtnhBBPnnKJ0_55ClHiMOp_dmuZBjbXnUy7zYIe0_H_R9n1nmOH7kclwhVMDO8umMIPjsVE-9NlMpa4ZQfIyewxiWBpJn0vXwA3fgxuOzFhKINgnVVZtSLvyXttfw5qgxgO4AMPsagNJcmbY8lKzT2H7OePqj733Z-A4C48hc
CitedBy_id crossref_primary_10_1016_S1773_035X_25_76280_2
Cites_doi 10.1002/cncr.32762
10.1056/nejmoa2027187
10.1016/s1470-2045(21)00336-3
10.1093/bioinformatics/btt755
10.1158/2159-8290.cd-16-1396
10.1056/nejmoa1612674
10.1200/jco.2014.59.4812
10.1200/jco.2014.60.7341
10.1158/1535-7163.mct-14-0983
10.1056/nejmoa1007056
10.1158/1078-0432.ccr-14-0603
10.1056/nejmoa1209124
10.1016/s1470-2045(16)00077-2
10.1016/j.ygyno.2023.05.059
10.1056/nejmoa1911440
10.1093/annonc/mdx703
10.1016/s0140-6736(06)69446-4
10.1200/jco.18.00545
10.1016/s1470-2045(20)30157-1
10.1159/000492710
10.1200/po.17.00002
10.1016/s1470-2045(20)30451-4
10.1159/000510241
10.1002/cncr.32876
10.1016/j.ejmech.2020.112995
10.1038/s41523-020-00174-9
10.4143/crt.2022.1026
10.1038/nm.4191
10.1016/s1470-2045(22)00284-4
10.1158/1078-0432.ccr-21-0327
10.1007/978-1-4939-9773-2_5
10.1056/nejmoa2212419
10.1093/annonc/mdz012
10.1002/onco.13829
10.1016/s1470-2045(22)00541-1
10.1016/j.annonc.2022.05.520
10.1200/jco.21.00003
10.1056/nejmoa1704795
10.1200/jco.21.02453
10.1016/j.annonc.2021.09.019
10.1158/1078-0432.ccr-11-3025
10.1158/1078-0432.ccr-15-2477
10.1097/pas.0000000000001450
10.1007/s00401-016-1545-1
10.1158/1078-0432.ccr-17-1337
10.1093/annonc/mdz131
10.1002/path.5372
10.1038/nature10166
10.1016/j.ejca.2021.11.021
10.1200/jco.2005.07.088
10.1038/s41416-019-0491-9
10.1056/nejmoa1412690
10.1056/nejmoa1817323
10.1056/nejmoa1411817
10.1016/j.eururo.2022.06.016
10.1158/1078-0432.ccr-19-0624
10.1200/jco.21.01323
10.1016/j.annonc.2022.05.009
10.1056/nejmoa0810699
10.1200/jco.19.02492
10.1200/po.17.00189
10.1038/s43018-020-0043-5
10.1001/jamaoncol.2016.6728
10.1016/j.esmoop.2021.100319
10.1158/1078-0432.ccr-17-3384
10.3389/fgene.2022.990244
10.1200/jco.20.01994
10.1056/nejmoa1408868
10.1038/nature05945
10.1200/jco.21.01455
10.1001/jamadermatol.2018.4940
10.1016/s1470-2045(20)30321-1
10.4143/crt.2023.446
10.1186/s12920-021-00909-y
10.1038/s41523-018-0066-6
10.1007/s00401-016-1646-x
10.2217/fon-2020-0737
10.1001/jamaoncol.2016.0264
10.1097/cmr.0000000000000099
10.1001/jamaoncol.2019.2963
10.1056/nejmoa1903387
10.1373/clinchem.2014.223677
10.1158/2159-8290.cd-19-0966
10.1016/s0140-6736(20)30934-x
10.3390/cancers13071491
10.1001/jamaoncol.2021.3836
10.4143/crt.2019.086
10.3390/cancers12041009
10.1016/s1470-2045(14)70178-0
10.1097/jto.0000000000000566
10.1016/s1470-2045(17)30608-3
10.1038/nature10760
10.1200/po.17.00084
10.1056/nejmoa1810858
10.1111/pcmr.12388
10.1200/jco.2016.67.5264
10.1158/2159-8290.cd-14-0623
10.1016/s1470-2045(16)30146-2
10.1038/s41586-022-05068-3
10.1200/jco.20.00762
10.3390/ijms23073995
10.1200/jco.2021.39.15_suppl.3007
10.1016/j.jtho.2021.11.025
10.1016/s1470-2045(14)70228-1
10.1016/s0140-6736(17)30123-x
10.1159/000478662
10.1038/nature25475
10.1056/nejmoa1802905
10.1016/j.jmoldx.2020.04.210
10.1016/s1470-2045(21)00247-3
10.3390/cancers9040039
10.1158/1078-0432.ccr-22-1749
10.1038/s41379-020-0488-1
10.1186/bcr3670
10.1093/jnci/djx118
10.1158/1078-0432.ccr-13-1746
10.1001/jamaoncol.2021.4761
10.1200/jco.2021.39.15_suppl.3003
10.1001/jama.2011.746
10.1200/jco.19.00368
10.1016/s1470-2045(19)30691-6
10.1186/s40164-017-0067-4
10.1093/annonc/mdx527
10.1038/s43018-022-00399-6
10.1016/s1470-2045(18)30142-6
10.1056/nejmoa1911361
10.1016/j.ccell.2020.10.001
10.1056/nejmoa1909707
10.1056/nejmoa1305275
10.1200/jco.19.02107
10.1016/s1470-2045(22)00603-9
10.1093/annonc/mdz116
10.1056/nejmoa2204619
10.1158/2159-8290.cd-14-0337
10.1200/jco.2020.38.15_suppl.5004
10.1056/nejmoa1413513
10.1001/jamaoncol.2016.1056
10.6004/jnccn.2017.0058
10.1016/s1470-2045(16)30392-8
10.1200/jco.2017.73.0143
10.1016/s1470-2045(21)00605-7
10.1200/jco.23.00434
10.1200/jco.20.00549
10.1016/j.annonc.2021.12.014
10.1038/oncsis.2015.28
10.1016/s1470-2045(20)30169-8
10.1038/s41467-021-22605-2
10.4143/crt.2021.1115
10.1016/j.ejca.2020.02.038
10.1016/s1470-2045(21)00034-6
10.1093/annonc/mdz291
10.1016/s2468-1253(22)00335-1
10.1002/ijc.31878
10.18632/oncotarget.13918
10.1016/j.jmoldx.2018.09.005
10.2217/fon-2022-0214
10.1158/1078-0432.ccr-21-1291
10.1158/1078-0432.ccr-18-1590
10.1016/s1470-2045(17)30679-4
10.1056/nejmoa0804385
10.1056/nejmoa1708539
10.1200/jco.20.02151
10.1136/jitc-2021-002551
10.1200/po.18.00039
10.1093/annonc/mdy058
10.1016/s1470-2045(21)00578-7
10.1200/jco.2016.67.2048
10.1158/1078-0432.ccr-17-1327
10.1038/bjc.2015.190
10.1016/s1470-2045(20)30269-2
10.3390/ijms23010348
10.1073/pnas.0709662105
10.1158/2159-8290.cd-20-1680
10.1158/1078-0432.ccr-19-0225
10.1186/s43556-022-00107-x
10.1186/s13073-017-0424-2
10.1016/s2468-1253(21)00196-5
10.1158/2159-8290.cd-19-0442
10.1038/s41416-022-01837-z
10.1186/s12916-022-02470-6
10.1136/ijgc-2020-001929
10.1200/jco.2012.47.7836
10.1158/2159-8290.cd-20-0522
10.1056/nejm200103153441101
10.1056/nejmoa0805019
10.1016/s1470-2045(20)30109-1
10.1038/bjc.2012.18
10.1016/s1470-2045(20)30445-9
10.1056/nejmoa2004413
10.1186/s13045-017-0411-5
10.1056/nejmoa2103425
10.1038/nrm2858
10.1038/s41467-020-20162-8
10.1200/po.21.00267
10.1200/jco.2017.76.9901
10.1093/annonc/mdy171
10.1158/1078-0432.ccr-14-3357
10.1056/nejmp1709968
10.1158/2159-8290.cd-23-0153
10.1016/s1470-2045(17)30180-8
10.1016/j.annonc.2019.11.018
ContentType Journal Article
Copyright 2024. This work is published under https://www.jpatholtm.org/articles/archive.php (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Korean Society of Pathologists/The Korean Society for Cytopathology 2024
Copyright_xml – notice: 2024. This work is published under https://www.jpatholtm.org/articles/archive.php (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Korean Society of Pathologists/The Korean Society for Cytopathology 2024
DBID AAYXX
CITATION
NPM
3V.
7XB
8FK
8G5
ABUWG
AFKRA
AZQEC
BENPR
BVBZV
CCPQU
DWQXO
GNUQQ
GUQSH
M2O
MBDVC
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
ADTOC
UNPAY
DOA
ACYCR
DOI 10.4132/jptm.2023.11.01
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
ProQuest Central (purchase pre-March 2016)
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni Edition)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
East & South Asia Database
ProQuest One Community College
ProQuest Central Korea
ProQuest Central Student
Research Library Prep
ProQuest Research Library
Research Library (Corporate)
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
DOAJ Directory of Open Access Journals
Korean Citation Index
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Basic
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Central (Alumni Edition)
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Central China
East & South Asia Database
ProQuest Central
ProQuest One Academic UKI Edition
ProQuest Central Korea
ProQuest Research Library
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList


Publicly Available Content Database
CrossRef
PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
EISSN 2383-7845
EndPage 164
ExternalDocumentID oai_kci_go_kr_ARTI_10551761
oai_doaj_org_article_44ffb81b584c45b583bff31f456ec2e9
10.4132/jptm.2023.11.01
PMC11261170
39026440
10_4132_jptm_2023_11_01
Genre Journal Article
Review
GrantInformation_xml – fundername: National Cancer Center
– fundername: Ministry of Health and Welfare
  grantid: HA22C0052
GroupedDBID 5-W
8G5
8JR
AAYXX
ABUWG
ACYCR
ADBBV
AFKRA
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BCNDV
BENPR
BPHCQ
BVBZV
CCPQU
CITATION
DIK
DWQXO
EF.
GNUQQ
GROUPED_DOAJ
GUQSH
HYE
KQ8
M2O
M48
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PUEGO
RNS
RPM
3V.
ADRAZ
IPNFZ
M~E
NPM
OK1
RIG
7XB
8FK
MBDVC
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
5PM
ADTOC
UNPAY
ID FETCH-LOGICAL-c453t-1315bc5c0c9a6322a8f34401ba5add09741e5eff8ca53f271a8b20c221c996283
IEDL.DBID UNPAY
ISSN 2383-7837
2383-7845
IngestDate Wed Jul 17 03:23:56 EDT 2024
Wed Aug 27 01:27:36 EDT 2025
Mon Sep 15 10:11:27 EDT 2025
Tue Sep 30 17:08:19 EDT 2025
Thu Sep 04 16:48:48 EDT 2025
Mon Jun 30 17:26:30 EDT 2025
Thu Jan 02 22:28:34 EST 2025
Wed Oct 01 04:01:26 EDT 2025
Thu Apr 24 23:03:48 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Next-generation sequencing
Solid cancer
Precision medicine
Korea
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
cc-by-nc
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c453t-1315bc5c0c9a6322a8f34401ba5add09741e5eff8ca53f271a8b20c221c996283
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
This article has been published jointly, with consent, in both Cancer Research and Treatment and Journal of Pathology and Translational Medicine.
ORCID 0000-0002-8694-4365
0000-0001-5897-8309
0000-0001-9959-0642
0000-0002-0299-7268
0000-0002-0139-9768
0000-0001-9467-461X
0000-0001-8766-2602
0000-0001-5151-5096
0000-0002-0351-2074
0000-0003-3458-1440
0000-0002-5847-7317
0000-0001-7987-4437
0000-0002-5115-1402
0000-0002-5718-3624
0000-0003-4299-5694
0000-0002-1357-7015
0000-0001-5651-7939
0000-0002-4347-4420
0000-0002-2656-0650
0000-0002-2523-9531
0000-0002-1451-8455
0000-0002-1667-7986
0000-0002-6504-9927
0000-0002-9044-8540
0000-0001-7704-5942
0000-0002-5721-1728
0000-0001-7694-1593
0000-0002-1583-4142
0000-0003-1336-3620
0000-0002-4064-4199
0000-0001-9376-359X
0000-0001-7544-0404
0000-0002-8749-2612
0000-0003-2776-5954
0000-0001-8439-1739
0000-0003-3064-7895
0000-0003-4220-6755
OpenAccessLink https://proxy.k.utb.cz/login?url=https://www.jpatholtm.org/upload/pdf/jptm-2023-11-01.pdf
PMID 39026440
PQID 3084910876
PQPubID 1146335
PageCount 18
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_10551761
doaj_primary_oai_doaj_org_article_44ffb81b584c45b583bff31f456ec2e9
unpaywall_primary_10_4132_jptm_2023_11_01
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11261170
proquest_miscellaneous_3082630399
proquest_journals_3084910876
pubmed_primary_39026440
crossref_citationtrail_10_4132_jptm_2023_11_01
crossref_primary_10_4132_jptm_2023_11_01
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-07-01
PublicationDateYYYYMMDD 2024-07-01
PublicationDate_xml – month: 07
  year: 2024
  text: 2024-07-01
  day: 01
PublicationDecade 2020
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
– name: Seoul
PublicationTitle Journal of pathology and translational medicine
PublicationTitleAlternate J Pathol Transl Med
PublicationYear 2024
Publisher Korean Society of Pathologists, Korean Society for Cytopathology
The Korean Society of Pathologists and the Korean Society for Cytopathology
Korean Society of Pathologists & the Korean Society for Cytopathology
대한병리학회
Publisher_xml – name: Korean Society of Pathologists, Korean Society for Cytopathology
– name: The Korean Society of Pathologists and the Korean Society for Cytopathology
– name: Korean Society of Pathologists & the Korean Society for Cytopathology
– name: 대한병리학회
References ref207
ref208
ref59
ref205
ref58
ref206
ref53
ref203
ref52
ref204
ref201
ref202
ref209
ref210
ref211
ref51
ref50
ref46
ref45
ref219
ref48
ref47
ref217
ref214
ref41
ref215
ref212
ref43
ref213
Coleman (ref148) 2017
ref7
Geyer (ref198) 2022
Bang (ref87) 2010
ref4
ref3
ref6
Fader (ref134) 2018
ref5
ref221
ref222
ref40
Rousseau (ref105) 2022
ref220
ref35
ref34
ref36
Le (ref216) 2017
ref31
ref30
ref33
ref32
ref38
ref23
ref26
ref25
ref20
ref22
ref27
ref29
ref200
Ettinger (ref8) 2022
ref128
ref129
ref126
ref96
ref127
ref99
ref124
ref98
ref125
Hussain (ref154) 2020
Kim (ref172) 2013
ref93
ref133
Skoulidis (ref54) 2021
ref92
ref95
ref131
ref94
ref132
ref91
ref90
ref89
ref139
ref86
ref137
ref85
Strickler (ref101) 2023
ref138
Murthy (ref71) 2020
Bidard (ref83) 2022
ref88
ref135
ref136
ref82
ref81
ref145
ref84
ref143
ref140
ref141
ref80
ref79
ref108
ref229
ref78
ref109
ref106
ref227
ref107
ref228
ref75
ref104
ref225
(ref28) 2021
ref226
ref77
ref102
ref223
Mirtavoos-Mahyari (ref239) 2019
ref103
ref224
Long (ref162) 2014
Camidge (ref37) 2018
ref111
ref232
ref70
ref112
ref233
ref73
ref230
ref72
ref110
ref231
Yun (ref39) 2020
ref68
ref67
ref117
ref238
ref69
ref118
ref64
ref115
ref236
ref63
ref116
ref237
ref66
ref113
ref234
ref65
ref114
ref235
Wolf (ref56) 2020
Paik (ref55) 2020
ref122
ref243
ref123
ref244
ref120
ref241
ref61
ref121
ref242
ref240
ref168
ref169
ref170
ref177
ref178
ref175
ref176
ref173
Gonzalez-Martin (ref142) 2019
ref174
ref171
ref179
ref180
ref181
Marabelle (ref9) 2020
Robson (ref76) 2017
ref188
ref189
Strickler (ref119) 2023
ref187
ref184
ref185
ref182
ref183
Soria (ref44) 2018
ref146
ref147
Chakravarty (ref21) 2017
ref155
ref156
ref153
ref151
Andre (ref74) 2019
ref152
Wagner (ref186) 2021
ref150
ref159
ref157
ref158
Zehir (ref2) 2017
ref166
ref167
ref164
Drilon (ref19) 2018
ref165
ref163
ref160
ref161
ref13
ref12
ref15
ref14
Pujade-Lauraine (ref149) 2017
ref11
ref10
Mirza (ref144) 2016
ref17
ref16
Kopetz (ref97) 2019
ref18
Gounder (ref24) 2022
Andre (ref100) 2020
Drilon (ref57) 2020
Samstein (ref218) 2019
Rosell (ref42) 2012
Li (ref62) 2022
ref1
Goyal (ref130) 2023
ref191
ref192
ref190
Park (ref49) 2021
ref199
ref195
ref196
ref193
ref194
Pennington (ref197) 2014
Drilon (ref60) 2020
References_xml – ident: ref115
  doi: 10.1002/cncr.32762
– ident: ref52
  doi: 10.1056/nejmoa2027187
– start-page: 1929
  volume-title: Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer
  year: 2019
  ident: ref74
– ident: ref131
  doi: 10.1016/s1470-2045(21)00336-3
– start-page: 703
  volume-title: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
  year: 2017
  ident: ref2
– ident: ref209
  doi: 10.1093/bioinformatics/btt755
– ident: ref4
  doi: 10.1158/2159-8290.cd-16-1396
– ident: ref29
  doi: 10.1056/nejmoa1612674
– ident: ref96
  doi: 10.1200/jco.2014.59.4812
– ident: ref112
  doi: 10.1200/jco.2014.60.7341
– ident: ref215
  doi: 10.1158/1535-7163.mct-14-0983
– ident: ref180
  doi: 10.1056/nejmoa1007056
– ident: ref6
  doi: 10.1158/1078-0432.ccr-14-0603
– ident: ref68
  doi: 10.1056/nejmoa1209124
– ident: ref50
  doi: 10.1016/s1470-2045(16)00077-2
– ident: ref137
  doi: 10.1016/j.ygyno.2023.05.059
– ident: ref153
  doi: 10.1056/nejmoa1911440
– start-page: 931
  volume-title: Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations
  year: 2020
  ident: ref55
– ident: ref31
  doi: 10.1093/annonc/mdx703
– ident: ref174
  doi: 10.1016/s0140-6736(06)69446-4
– ident: ref111
  doi: 10.1200/jco.18.00545
– ident: ref126
  doi: 10.1016/s1470-2045(20)30157-1
– ident: ref233
  doi: 10.1159/000492710
– start-page: 1250
  volume-title: Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
  year: 2022
  ident: ref198
– start-page: 3660
  volume-title: nab-Sirolimus for patients with malignant perivascular epithelioid cell tumors
  year: 2021
  ident: ref186
– ident: ref3
  doi: 10.1200/po.17.00002
– ident: ref183
  doi: 10.1016/s1470-2045(20)30451-4
– ident: ref185
  doi: 10.1159/000510241
– ident: ref236
  doi: 10.1002/cncr.32876
– ident: ref33
  doi: 10.1016/j.ejmech.2020.112995
– ident: ref85
  doi: 10.1038/s41523-020-00174-9
– ident: ref234
  doi: 10.4143/crt.2022.1026
– ident: ref211
  doi: 10.1038/nm.4191
– ident: ref82
  doi: 10.1016/s1470-2045(22)00284-4
– start-page: 3406
  volume-title: Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma
  year: 2022
  ident: ref24
– ident: ref220
  doi: 10.1158/1078-0432.ccr-21-0327
– ident: ref206
  doi: 10.1007/978-1-4939-9773-2_5
– ident: ref103
  doi: 10.1056/nejmoa2212419
– ident: ref195
  doi: 10.1093/annonc/mdz012
– ident: ref194
  doi: 10.1002/onco.13829
– ident: ref18
  doi: 10.1016/s1470-2045(22)00541-1
– ident: ref232
  doi: 10.1016/j.annonc.2022.05.520
– ident: ref118
  doi: 10.1200/jco.21.00003
– ident: ref36
  doi: 10.1056/nejmoa1704795
– ident: ref92
  doi: 10.1200/jco.21.02453
– ident: ref80
  doi: 10.1016/j.annonc.2021.09.019
– ident: ref176
  doi: 10.1158/1078-0432.ccr-11-3025
– ident: ref199
  doi: 10.1158/1078-0432.ccr-15-2477
– ident: ref202
  doi: 10.1097/pas.0000000000001450
– ident: ref26
  doi: 10.1007/s00401-016-1545-1
– start-page: 2154
  volume-title: Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer
  year: 2016
  ident: ref144
– ident: ref78
  doi: 10.1158/1078-0432.ccr-17-1337
– start-page: PO.17.00011
  volume-title: OncoKB: a precision oncology knowledge base
  year: 2017
  ident: ref21
– ident: ref59
  doi: 10.1093/annonc/mdz131
– ident: ref136
  doi: 10.1002/path.5372
– ident: ref201
  doi: 10.1038/nature10166
– ident: ref64
  doi: 10.1016/j.ejca.2021.11.021
– ident: ref178
  doi: 10.1200/jco.2005.07.088
– start-page: 409
  volume-title: Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
  year: 2017
  ident: ref216
– ident: ref238
  doi: 10.1038/s41416-019-0491-9
– ident: ref11
  doi: 10.1056/nejmoa1412690
– start-page: 261
  volume-title: Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials
  year: 2020
  ident: ref60
– ident: ref150
  doi: 10.1056/nejmoa1817323
– ident: ref30
  doi: 10.1056/nejmoa1411817
– start-page: 597
  volume-title: Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer
  year: 2020
  ident: ref71
– ident: ref25
  doi: 10.1016/j.eururo.2022.06.016
– start-page: 687
  volume-title: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
  year: 2010
  ident: ref87
– ident: ref237
  doi: 10.1158/1078-0432.ccr-19-0624
– ident: ref63
  doi: 10.1200/jco.21.01323
– ident: ref135
  doi: 10.1016/j.annonc.2022.05.009
– ident: ref41
  doi: 10.1056/nejmoa0810699
– ident: ref184
  doi: 10.1200/jco.19.02492
– ident: ref207
  doi: 10.1200/po.17.00189
– ident: ref226
  doi: 10.1038/s43018-020-0043-5
– ident: ref175
  doi: 10.1001/jamaoncol.2016.6728
– ident: ref34
  doi: 10.1016/j.esmoop.2021.100319
– ident: ref171
  doi: 10.1158/1078-0432.ccr-17-3384
– ident: ref204
  doi: 10.3389/fgene.2022.990244
– ident: ref98
  doi: 10.1200/jco.20.01994
– ident: ref160
  doi: 10.1056/nejmoa1408868
– ident: ref35
  doi: 10.1038/nature05945
– ident: ref61
  doi: 10.1200/jco.21.01455
– start-page: 523
  volume-title: Olaparib for metastatic breast cancer in patients with a germline BRCA mutation
  year: 2017
  ident: ref76
– ident: ref179
  doi: 10.1001/jamadermatol.2018.4940
– ident: ref14
  doi: 10.1016/s1470-2045(20)30321-1
– ident: ref235
  doi: 10.4143/crt.2023.446
– ident: ref229
  doi: 10.1186/s12920-021-00909-y
– ident: ref203
  doi: 10.1038/s41523-018-0066-6
– start-page: 2207
  volume-title: Pembrolizumab in microsatellite-instability-high advanced colorectal cancer
  year: 2020
  ident: ref100
– ident: ref27
  doi: 10.1007/s00401-016-1646-x
– ident: ref89
  doi: 10.2217/fon-2020-0737
– ident: ref189
  doi: 10.1001/jamaoncol.2016.0264
– ident: ref170
  doi: 10.1097/cmr.0000000000000099
– ident: ref106
  doi: 10.1001/jamaoncol.2019.2963
– ident: ref117
  doi: 10.1056/nejmoa1903387
– ident: ref208
  doi: 10.1373/clinchem.2014.223677
– ident: ref73
  doi: 10.1158/2159-8290.cd-19-0966
– ident: ref163
  doi: 10.1016/s0140-6736(20)30934-x
– ident: ref244
  doi: 10.3390/cancers13071491
– ident: ref127
  doi: 10.1001/jamaoncol.2021.3836
– ident: ref156
  doi: 10.4143/crt.2019.086
– ident: ref225
  doi: 10.3390/cancers12041009
– start-page: 241
  volume-title: Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer
  year: 2022
  ident: ref62
– start-page: 202
  volume-title: Tumor mutational load predicts survival after immunotherapy across multiple cancer types
  year: 2019
  ident: ref218
– ident: ref69
  doi: 10.1016/s1470-2045(14)70178-0
– ident: ref181
  doi: 10.1097/jto.0000000000000566
– ident: ref43
  doi: 10.1016/s1470-2045(17)30608-3
– ident: ref192
  doi: 10.1038/nature10760
– ident: ref213
  doi: 10.1200/po.17.00084
– start-page: 2345
  volume-title: Survival with olaparib in metastatic castration-resistant prostate cancer
  year: 2020
  ident: ref154
– start-page: 482
  volume-title: Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor
  year: 2013
  ident: ref172
– ident: ref145
  doi: 10.1056/nejmoa1810858
– ident: ref168
  doi: 10.1111/pcmr.12388
– start-page: 1949
  volume-title: Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
  year: 2017
  ident: ref148
– ident: ref108
  doi: 10.1200/jco.2016.67.5264
– ident: ref151
  doi: 10.1158/2159-8290.cd-14-0623
– ident: ref12
  doi: 10.1016/s1470-2045(16)30146-2
– ident: ref7
  doi: 10.1038/s41586-022-05068-3
– ident: ref15
  doi: 10.1200/jco.20.00762
– ident: ref158
  doi: 10.3390/ijms23073995
– ident: ref167
  doi: 10.1200/jco.2021.39.15_suppl.3007
– ident: ref45
  doi: 10.1016/j.jtho.2021.11.025
– ident: ref147
  doi: 10.1016/s1470-2045(14)70228-1
– ident: ref51
  doi: 10.1016/s0140-6736(17)30123-x
– ident: ref23
  doi: 10.1159/000478662
– ident: ref72
  doi: 10.1038/nature25475
– ident: ref77
  doi: 10.1056/nejmoa1802905
– ident: ref242
  doi: 10.1016/j.jmoldx.2020.04.210
– ident: ref58
  doi: 10.1016/s1470-2045(21)00247-3
– ident: ref116
  doi: 10.3390/cancers9040039
– start-page: 1632
  volume-title: Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer
  year: 2019
  ident: ref97
– ident: ref227
  doi: 10.1158/1078-0432.ccr-22-1749
– start-page: 1274
  volume-title: Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
  year: 2017
  ident: ref149
– ident: ref22
  doi: 10.1038/s41379-020-0488-1
– ident: ref200
  doi: 10.1186/bcr3670
– ident: ref230
  doi: 10.1093/jnci/djx118
– ident: ref169
  doi: 10.1158/1078-0432.ccr-13-1746
– ident: ref48
  doi: 10.1001/jamaoncol.2021.4761
– ident: ref124
  doi: 10.1200/jco.2021.39.15_suppl.3003
– ident: ref164
  doi: 10.1001/jama.2011.746
– ident: ref81
  doi: 10.1200/jco.19.00368
– ident: ref20
  doi: 10.1016/s1470-2045(19)30691-6
– ident: ref173
  doi: 10.1186/s40164-017-0067-4
– ident: ref190
  doi: 10.1093/annonc/mdx527
– ident: ref38
  doi: 10.1038/s43018-022-00399-6
– ident: ref159
  doi: 10.1016/s1470-2045(18)30142-6
– ident: ref146
  doi: 10.1056/nejmoa1911361
– ident: ref219
  doi: 10.1016/j.ccell.2020.10.001
– start-page: 1
  volume-title: Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study
  year: 2020
  ident: ref9
– start-page: 764
  volume-title: Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas
  year: 2014
  ident: ref197
– ident: ref143
  doi: 10.1056/nejmoa1909707
– ident: ref95
  doi: 10.1056/nejmoa1305275
– ident: ref40
  doi: 10.1200/jco.19.02107
– ident: ref90
  doi: 10.1016/s1470-2045(22)00603-9
– ident: ref224
  doi: 10.1093/annonc/mdz116
– start-page: 14
  volume-title: Circulating free DNA concentration as a marker of disease recurrence and metastatic potential in lung cancer
  year: 2019
  ident: ref239
– start-page: 2391
  volume-title: Niraparib in patients with newly diagnosed advanced ovarian cancer
  year: 2019
  ident: ref142
– ident: ref53
  doi: 10.1056/nejmoa2204619
– ident: ref47
  doi: 10.1158/2159-8290.cd-14-0337
– ident: ref157
  doi: 10.1200/jco.2020.38.15_suppl.5004
– ident: ref70
  doi: 10.1056/nejmoa1413513
– ident: ref152
  doi: 10.1001/jamaoncol.2016.1056
– start-page: 731
  volume-title: Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children
  year: 2018
  ident: ref19
– start-page: 1877
  volume-title: Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma
  year: 2014
  ident: ref162
– start-page: 2027
  volume-title: Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer
  year: 2018
  ident: ref37
– ident: ref123
  doi: 10.6004/jnccn.2017.0058
– ident: ref182
  doi: 10.1016/s1470-2045(16)30392-8
– ident: ref84
  doi: 10.1200/jco.2017.73.0143
– ident: ref102
  doi: 10.1016/s1470-2045(21)00605-7
– ident: ref120
  doi: 10.1200/jco.23.00434
– ident: ref139
  doi: 10.1200/jco.20.00549
– start-page: 497
  volume-title: Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology
  year: 2022
  ident: ref8
– ident: ref17
  doi: 10.1016/j.annonc.2021.12.014
– start-page: 1435
  volume-title: PD-1 blockade in solid tumors with defects in polymerase epsilon
  year: 2022
  ident: ref105
– ident: ref121
  doi: 10.1038/oncsis.2015.28
– start-page: 496
  volume-title: Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
  year: 2023
  ident: ref101
– year: 2021
  ident: ref28
– start-page: 2044
  volume-title: Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu
  year: 2018
  ident: ref134
– ident: ref86
  doi: 10.1016/s1470-2045(20)30169-8
– ident: ref231
  doi: 10.1038/s41467-021-22605-2
– start-page: 944
  volume-title: Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer
  year: 2020
  ident: ref56
– ident: ref1
  doi: 10.4143/crt.2021.1115
– ident: ref223
  doi: 10.1016/j.ejca.2020.02.038
– ident: ref75
  doi: 10.1016/s1470-2045(21)00034-6
– ident: ref109
  doi: 10.1093/annonc/mdz291
– ident: ref132
  doi: 10.1016/s2468-1253(22)00335-1
– ident: ref222
  doi: 10.1002/ijc.31878
– start-page: 3391
  volume-title: Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study
  year: 2021
  ident: ref49
– ident: ref210
  doi: 10.18632/oncotarget.13918
– start-page: 3246
  volume-title: Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial
  year: 2022
  ident: ref83
– start-page: 228
  volume-title: Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma
  year: 2023
  ident: ref130
– ident: ref212
  doi: 10.1016/j.jmoldx.2018.09.005
– ident: ref133
  doi: 10.2217/fon-2022-0214
– ident: ref187
  doi: 10.1158/1078-0432.ccr-21-1291
– ident: ref65
  doi: 10.1158/1078-0432.ccr-18-1590
– ident: ref13
  doi: 10.1016/s1470-2045(17)30679-4
– ident: ref93
  doi: 10.1056/nejmoa0804385
– ident: ref161
  doi: 10.1056/nejmoa1708539
– ident: ref79
  doi: 10.1200/jco.20.02151
– ident: ref243
  doi: 10.1136/jitc-2021-002551
– ident: ref125
  doi: 10.1200/po.18.00039
– ident: ref140
  doi: 10.1093/annonc/mdy058
– ident: ref16
  doi: 10.1016/s1470-2045(21)00578-7
– ident: ref113
  doi: 10.1200/jco.2016.67.2048
– ident: ref196
  doi: 10.1158/1078-0432.ccr-17-1327
– ident: ref138
  doi: 10.1038/bjc.2015.190
– ident: ref177
  doi: 10.1016/s1470-2045(20)30269-2
– ident: ref193
  doi: 10.3390/ijms23010348
– start-page: 33
  volume-title: Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer
  year: 2023
  ident: ref119
– ident: ref46
  doi: 10.1073/pnas.0709662105
– ident: ref214
  doi: 10.1158/2159-8290.cd-20-1680
– ident: ref228
  doi: 10.1158/1078-0432.ccr-19-0225
– ident: ref32
  doi: 10.1186/s43556-022-00107-x
– ident: ref221
  doi: 10.1186/s13073-017-0424-2
– ident: ref129
  doi: 10.1016/s2468-1253(21)00196-5
– ident: ref91
  doi: 10.1158/2159-8290.cd-19-0442
– ident: ref241
  doi: 10.1038/s41416-022-01837-z
– ident: ref66
  doi: 10.1186/s12916-022-02470-6
– start-page: 813
  volume-title: Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer
  year: 2020
  ident: ref57
– start-page: 3287
  volume-title: Repotrectinib exhibits potent antitumor activity in treatment-naive and solvent-front-mutant ROS1-rearranged non-small cell lung cancer
  year: 2020
  ident: ref39
– ident: ref141
  doi: 10.1136/ijgc-2020-001929
– ident: ref165
  doi: 10.1200/jco.2012.47.7836
– ident: ref217
  doi: 10.1158/2159-8290.cd-20-0522
– ident: ref67
  doi: 10.1056/nejm200103153441101
– ident: ref94
  doi: 10.1056/nejmoa0805019
– ident: ref128
  doi: 10.1016/s1470-2045(20)30109-1
– ident: ref122
  doi: 10.1038/bjc.2012.18
– ident: ref10
  doi: 10.1016/s1470-2045(20)30445-9
– ident: ref88
  doi: 10.1056/nejmoa2004413
– ident: ref5
  doi: 10.1186/s13045-017-0411-5
– ident: ref155
  doi: 10.1056/nejmoa2103425
– ident: ref191
  doi: 10.1038/nrm2858
– ident: ref240
  doi: 10.1038/s41467-020-20162-8
– ident: ref104
  doi: 10.1200/po.21.00267
– ident: ref99
  doi: 10.1200/jco.2017.76.9901
– ident: ref107
  doi: 10.1093/annonc/mdy171
– ident: ref114
  doi: 10.1158/1078-0432.ccr-14-3357
– ident: ref205
  doi: 10.1056/nejmp1709968
– start-page: 239
  volume-title: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
  year: 2012
  ident: ref42
– start-page: 2371
  volume-title: Sotorasib for lung cancers with KRAS p.G12C mutation
  year: 2021
  ident: ref54
– ident: ref188
  doi: 10.1158/2159-8290.cd-23-0153
– ident: ref166
  doi: 10.1016/s1470-2045(17)30180-8
– ident: ref110
  doi: 10.1016/j.annonc.2019.11.018
– start-page: 113
  volume-title: Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer
  year: 2018
  ident: ref44
SSID ssj0001453649
Score 2.2967246
SecondaryResourceType review_article
Snippet In recent years, next-generation sequencing (NGS)–based genetic testing has become crucial in cancer care. While its primary objective is to identify...
In recent years, next-generation sequencing (NGS)-based genetic testing has become crucial in cancer care. While its primary objective is to identify...
SourceID nrf
doaj
unpaywall
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 147
SubjectTerms Biomarkers
Bone cancer
Clinical medicine
Clinical trials
Ewings sarcoma
FDA approval
Genes
Genetic testing
Kidney cancer
korea
Metastasis
Mutation
next-generation sequencing
Oncology
Patients
Precision medicine
Regulatory approval
Review
Rhabdomyosarcoma
solid cancer
Tumors
병리학
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nj9MwELXQXuCCQHwFFjQIDnDIbmI7acoNEKsFtIAEK-3Nclx76W7XrfohxG_gT_PGSautAO2FU6raaRrP2PNe4nkjxPNRPWSgWud-oItcN63M26Bc7oCOK6esl2k34dGn-vBYfzipTi6V-uI9YZ08cDdw-1qH0AJbIVA6XeGg2hBUGRD4vZM-pe4hjF0iU-npiq5UnbAvQpLKB6Bhna4P1my5fzZbchK6VHss4FluhaSk3I9AE-fhb6Dzz72T11dxZn_-sJPJpcB0cEvc7BElve7u5La45uMd8avX-5zQOg2KmPpeXPi-iNKCgFYJ6I9WC0_TQJEp8GkSoeZ26vdYI7LROFIvv7ogfm5L8NfxiBw7zPwVWTqbjuOSutcPxAkr9PHr0WeycYQPX-6K44N3394e5n3dhRwjrLg6fVm1rnKFG9oaE942QWnwsNZWWA0LMJDSVz6ExtlKBTkoLUxcOClLB_YEvHJP7MRp9A8ESYZYNgTbaM9aaugHgqOxkjgr3WiYib310BvXi5JzbYyJATlhWxm2lWFbgauYoszEi80Js06P499d37AtN91YSDt9AfcyvXuZq9wrE8_gCebcjdP5fDydmvO5Ad14b7i6aDmocandtaeYfg1YGFU0GmAM4SYTTzfNmL38SsZGP12lPrIGihjiQvc7x9r8XzUsGK0WmWi2XG7rhrZb4vh7UgjnvDAuKZSJlxvvvGq4Hv6P4XokbuAXdbefeVfsLOcr_xiobdk-SRP0Nw48Poo
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwELbK9gAXVMQrUNAgOMAhbWI72SwSQhS1KqAuFVCpN8tx7GXbrbPdhxC_gT_NTOJsWfE6JYodJbbHM9_Y428Ye1blAwKqeWz7MollUfK4dMLEBtFxZoS2vIkmPBrmhyfy_Wl2usGG3VkYCqvsdGKjqKva0Br5rkgKiaYNJ-_r6WVMWaNod7VLoaFDaoXqVUMxdo1tcsqq3GObe_vD409Xqy4yE3mDidFUibiP7lnL94O6nO-eTRd0OJ2LHSL2TNdMVcPojwbIz9yfwOjvMZXXl36qv3_Tk8kvButgi90MSBPetKJxi21Yf5v9CDygE-iORwG5xBcXNiRXmgOiWEBUCMu5hdqBJ9d41JBTUzmE2Gu0eDD2EGhZ50DruYByPK7AkCDNXoKGs3rsF9BuSwAdZIEPn48-gvYV3hzfYScH-1_eHsYhH0NssNsoa32alSYziRnoHBWBLpyQ6J-VOkMtmaBnktrMOlcYnQnH-6nGoU8M56lBrwpxzF3W87W39xlwgl7aOV1ISxxrWA8dH4kaxmhuqkHEdrquVyaQlVPOjIlCp4XGStFYKRor9GFUkkbs-eqFacvT8feqezSWq2pEsN08qGcjFearktK5EiE94jNsPF5E6ZxIHeJNa7jFH3yKkqDOzbh5n66jWp3PFLoh7xRlHU37OX5qu5MUFXTDXF1JcsSerIpxVtNWjfa2XjZ1eI7oYoAfutcK1up_xSAhFJtErFgTubUGrZf48deGOZzOi1GqoYi9WEnn_7rrwb_b8JDdwLqyjWDeZr3FbGkfIU5blI_D5PsJ0pQ8FA
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nj9MwELXQcoALAvFV2EVGcIBDSmI7acoFAWK1gApIUGlvluPapbtZp5u2gv0N_GneJGmhoogLp0Sx8zUee95L7DeMPZ5kQwKqWeQGKo5UXoio8NJGFug4tdI40cwmHH3Ijsbq3XF6_CsdUGfAxU5qR_mkxnXZ_35-8QIdHvi1jyFYPDuZL2lNuZB90uMEFbqMsCTIxUcd1m8-uKhUZg0cRpSS0QDMrJX62XWNrSjViPkj9oTa78Khf06nvLIKc3PxzZTlb7Hq8Dq71oFM_rL1ihvskgs32Y9OArTk65VRnNjw2Znr8iotOAAsByDkq4XjleeBWPG00aWmct5Nu0aw47PAO0XWBadPuRwuPJtwSz5UP-eGn1SzsOTtHwlOa1j4-8-jj9yECXY-3WLjwzdfXh9FXSqGyMJslLA-SQub2tgOTYYxwOReKlCzwqQYIGOQksSlzvvcmlR6MUgMWj22QiQWhAoQ5jbbC1VwdxkXhLqM9yZXjuTVUA-cR2FwsUbYybDH-mvTa9vplFO6jFKDr1BbaWorTW0F-qLjpMeebE6YtxIdf6_6itpyU420tZsDVT3VXVfVSnlfAM0DmuHlsZGF9zLxgJrOCocHfARP0Kd21pxP22mlT2sNBvJWU8LRZJDhVvtrT9Frr9YyzhXwGSJQjz3cFKND018aE1y1auqIDMBiiBvdaR1r87xyGBOAjXss33K5rRfaLgmzr41oOC0VoyxDPfZ0453_Mte9_2Gu--wqrqjaKc77bG9Zr9wBgNyyeNB00J-qI0Xv
  priority: 102
  providerName: Scholars Portal
Title Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP
URI https://www.ncbi.nlm.nih.gov/pubmed/39026440
https://www.proquest.com/docview/3084910876
https://www.proquest.com/docview/3082630399
https://pubmed.ncbi.nlm.nih.gov/PMC11261170
https://www.jpatholtm.org/upload/pdf/jptm-2023-11-01.pdf
https://doaj.org/article/44ffb81b584c45b583bff31f456ec2e9
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003101610
UnpaywallVersion publishedVersion
Volume 58
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Journal of Pathology and Translational Medicine, 2024, 58(4), , pp.147-164
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 2383-7845
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001453649
  issn: 2383-7837
  databaseCode: KQ8
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2383-7845
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001453649
  issn: 2383-7837
  databaseCode: DOA
  dateStart: 19850101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 2383-7845
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001453649
  issn: 2383-7837
  databaseCode: DIK
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVERR
  databaseName: KoreaMed Open Access
  customDbUrl:
  eissn: 2383-7845
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001453649
  issn: 2383-7837
  databaseCode: 5-W
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://koreamed.org/journals
  providerName: Korean Association of Medical Journal Editors
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 2383-7845
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001453649
  issn: 2383-7837
  databaseCode: RPM
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: East & South Asia Database
  customDbUrl:
  eissn: 2383-7845
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0001453649
  issn: 2383-7837
  databaseCode: BVBZV
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/eastsouthasia
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 2383-7845
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001453649
  issn: 2383-7837
  databaseCode: BENPR
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVFZP
  databaseName: Scholars Portal Journals: Open Access
  customDbUrl:
  eissn: 2383-7845
  dateEnd: 20250531
  omitProxy: true
  ssIdentifier: ssj0001453649
  issn: 2383-7837
  databaseCode: M48
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELaW9gAXHuKxhaUyggMcks3DSVNuu2hXC6ilAlbaPVmOYy9tU6dqEyH4C_xpZhy3ojyE4NKksfOwM575Jh5_Q8izIh0iUE09NWCBx7I88nIdS08COk5kLFRkowlH4_TsnL25SC72SLZZC4NhlTNMxluV9cLO5DfLshLF4bLQh7NlvfAw33e7GMyHY9dIN8WppQ7pno8nR5c2l1wWe4PM0mW6fZa0rD6gsSN7FR-v4iN9Z7hjkCxvP5gZs9K_g5y_Rk5eb8xSfPksyvIHs3R6i1xuGtRGo8z9ps59-fUnrsf_afFtctNhVXrUCtcdsqfMXfLNMYmWdLPAiqJTvVgol55pTQEHU8CVtFkrWmlq0Lm-svTWWE5d9DbYTDo11BG7ril-EaYwEqYFlSiKq5dU0Fk1NTVtJzYoLoWhbz-M3lFhCtiZ3CPnpycfX515LqODJ1kSY977MMllIgM5FCmoEpHpmIGHl4sE9GwAvk2oEqV1JkUS62gQChCeQEZRKMEvAyR0n3RMZdQ-oRGCN6G1yJhCljaoB64TAx0lRSSLYY_4m9fKpaM7x6wbJQe3B-WAY99y7FvwgngQ9sjz7QnLlunjz1WPUU621ZCi2x6At8fdiOeMaZ2DUwAIDxoPmzjXOg41IFYlIwUP-BSkjM_l1J6P26uKz1ccHJnXHPOWhoMUbnWwkULutMuax0HGAOaBIeuRJ9ti0As42SOMqhpbJ0oBnwzhRg9aod0-bzwMEAcHPZLtiPNOg3ZLzPST5R7HFWeYrKhHXmwl_2_d9fAf6j4iN-APawOiD0inXjXqMcC-Ou-T7vHJePK-bz-bwO-IZX036r8DzadZ6A
linkProvider Unpaywall
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jc9MwFNaU9FAuLMOWUkAMy8DBqS3ZjsMMBwJ0EtIUZmg7HS5CVqQ0TSqHLNMpf4H_wl_hL_GeLaeE9dQDJ2csyVrylu9JT-8R8rAXNxCoxp6uh74XJinzUsOVpwAdR4pLzXJvwu5O3NoL3xxEByvka3kXBt0qS5mYC-pepnCPfJP7SQiqDZjXeVB29OkJ2GfT5-1X8Gc-Ymzr9e7LludSCHgqjDgmWg-iVEXKVw0ZA-3KxPAQTIpURsDYPoDpQEfamETJiBtWDySM1leMBQoMAVC98N3H408eZqnC01yXsuMCWU3wwLZCVpv7zQ_7Z7s60GucY25Qhdyrg_lXxBMCXcE2j8YzvPzOeA0DhwZLqjDPGAAKzk7M78Durz6ba3M7lqcncjT6QSFuXSbfyqUs_GCGtfksranPP0WZ_H_W-gq55LA5fVEw01Wyou018sVFTh3R8kIZxU2E42Pt0lFNKeB-CjiazqeaZoZa3Ezo5-G8sZw6b3XACHRgqQtkO6W4A06B8wc9qpD1Js-opEfZwM5ocZBD8eoP7bzvvqXS9uDHu-tk71yW5Aap2MzqW4QyBKvSGJmEGqPSQT0wFUOQyUoy1WtUSa0kJqFceHfMMjISYOYh9QmkPoHUB1af8IMqebJoMC4im_y5ahOpc1ENQ5LnL7JJXzgJJ8LQmBSMIEC0MHl48NQYHhhA6FoxDQN8ALQthmqQt8dnPxPDiQDDrS0wT2tQj6GrjZIkhZOmU3FGj1Vyf1EMchAPt6TV2Tyvw2LAYw3o6GbBKovx8oaPuN-vkmSJiZYmtFxiB4d5rHW8YYfJmark6YLf_rVc63-fwz2y1trtbovt9k7nNrkI7cLC_3uDVGaTub4DKHeW3nWihZKP58103wEdvrWs
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGJgEvXMStMMAIkOAhbWI7aYqEEGVUK2VjEmyaeDGOY5euXVJ60TT-Av-Iv8Kf4ZzE6SjXpz3wlKq269g9l-8cH59DyIM0aiFQjTzTFL4n4oR5ieXa04COQ82VYUU04dZ2tLkrXu2H-yvka3UXBsMqK5lYCOo01-gjb3A_FqDagHkb1oVF7Gx0no0_eVhBCk9aq3IaJYn0zPERmG_Tp90N-K8fMtZ5-e7FpucqDHhahBzrsAdhokPt65aKgLRVbLkAiyNRIfC9D1g7MKGxNtYq5JY1AwWL8TVjgQY7ATQz_O4ZshZHTQEctdbea7_fO_HwwBRRgb9BLXKvCaZgmVsI9AZrHIxneBGe8TomEQ2W1GJRPQCUXTaxvwO-v8ZvnptnY3V8pEajH5Rj5yL5Vm1rGRMzrM9nSV1__inj5P-575fIBYfZ6fOSyS6TFZNdIV9cRtURrS6aUXQuHB4aV6ZqSsEeoICv6XxqaG5phk6GfpHmG9upi2IH7EAHGXUJbqcUPeMUJMIgpRpZcvKEKnqQD7IZLQ94KF4Jor23W2-oylL4sHOV7J7K-q-R1SzPzA1CGYJYZa2KhcFsddAPTEgBslorptNWjdQrwpLapX3H6iMjCeYfUqJESpRIiWANSj-okUeLAeMy48mfu7aRUhfdMFV58UU-6Usn-aQQ1iZgHAHShcXDgyfW8sACcjeaGXjB-0DncqgHxXh89nM5nEgw6LoS67cGzQimWq_IUzopO5UntFkj9xbNIB_x0EtlJp8XfVgEOK0FE10v2Wbxvrzloz3g10i8xFBLC1puyQYfixzsePMOizbVyOMF7_1ru27-fQ13yVngLPm6u927Rc7DMFGGha-T1dlkbm4D-J0ld5yUoeTDaTPYd1bkvnw
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbK9gAXHuLRQEFGcIBD0jycbJZbQVQF1FIJVmpPluPYZXezzmo3EYK_wJ9mxnEilocQnPKw87AznvkmHn9DyNMymyBQzXw1ZqHP8iL2C51IXwI6TmUiVGyjCU9Os-Mpe3uenu-QvF8Lg2GVc0zGW1fN0s7kt6uqFuXBqtQH81Wz9DHfd7cYLIBzV8huhlNLI7I7PT07vLC55PLEH-eWLtPts7Rj9QGNHdu7BHiXAOk7oy2DZHn7wcyYtf4d5Pw1cvJqa1biy2dRVT-YpaMb5KJvUBeNsgjapgjk15-4Hv-nxTfJdYdV6WEnXLfIjjK3yTfHJFrRfoEVRad6uVQuPdOGAg6mgCtpu1G01tSgc31p6a2xnLrobbCZdGaoI3bdUPwjTGEkzEoqURTXL6ig83pmGtpNbFBcCkPffTh5T4UpYefsDpkevf746th3GR18ydIE895HaSFTGcqJyECViFwnDDy8QqSgZ0PwbSKVKq1zKdJEx-NIgPCEMo4jCX4ZIKG7ZGRqo_YIjRG8Ca1FzhSytEE9cJ0Y6CgpYllOPBL0n5VLR3eOWTcqDm4PygHHvuXYt-AF8TDyyLPhglXH9PHnqi9RToZqSNFtT8DX427Ec8a0LsApAIQHjYdNUmidRBoQq5Kxghd8AlLGF3Jmr8ftZc0Xaw6OzBuOeUujcQaP2u-lkDvtsuFJmDOAeWDIPPJ4KAa9gJM9wqi6tXXiDPDJBB50rxPa4X2TSYg4OPRIviXOWw3aLjGzT5Z7HFecYbIijzwfJP9v3XX_H-o-INfggHUB0ftk1Kxb9RBgX1M8ciP8O-7aVn8
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+practice+recommendations+for+the+use+of+next-generation+sequencing+in+patients+with+solid+cancer%3A+a+joint+report+from+KSMO+and+KSP&rft.jtitle=Journal+of+pathology+and+translational+medicine&rft.au=Miso+Kim&rft.au=Hyo+Sup+Shim&rft.au=Sheehyun+Kim&rft.au=In+Hee+Lee&rft.date=2024-07-01&rft.pub=Korean+Society+of+Pathologists+%26+the+Korean+Society+for+Cytopathology&rft.issn=2383-7837&rft.eissn=2383-7845&rft.volume=58&rft.issue=4&rft.spage=147&rft.epage=164&rft_id=info:doi/10.4132%2Fjptm.2023.11.01&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_44ffb81b584c45b583bff31f456ec2e9
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2383-7837&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2383-7837&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2383-7837&client=summon